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A B S T R A C T
Aberrant NF-κB activity drives oncogenesis and cell survival in multiple myeloma (MM) and many other cancers.
However, despite an aggressive effort by the pharmaceutical industry over the past 30 years, no specific IκBα kinase
(IKK)β/NF-κB inhibitor has been clinically approved, due to the multiple dose-limiting toxicities of conventional NF-κB-
targeting drugs. To overcome this barrier to therapeutic NF-κB inhibition, we developed the first-in-class growth arrest
and DNA-damage-inducible (GADD45)β/mitogen-activated protein kinase kinase (MKK)7 inhibitor, DTP3, which tar-
gets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway. As a result, DTP3 specifically
kills MM cells, ex vivo and in vivo, ablating MM xenografts in mice, with no apparent adverse effects, nor evident toxicity
to healthy cells. Here, we report the results from the preclinical regulatory pharmacodynamic (PD), safety pharma-
cology, pharmacokinetic (PK), and toxicology programmes of DTP3, leading to the approval for clinical trials in on-
cology. These results demonstrate that DTP3 combines on-target-selective pharmacology, therapeutic anticancer effi-
cacy, favourable drug-like properties, long plasma half-life and good bioavailability, with no target-organs of toxicity
and no adverse effects preclusive of its clinical development in oncology, upon daily repeat-dose administration in both
rodent and non-rodent species. Our study underscores the clinical potential of DTP3 as a conceptually novel candidate
therapeutic selectively blocking NF-κB survival signalling in MM and potentially other NF-κB-driven cancers.
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1. Introduction
NF-κB transcription factors are aberrantly activated in most human
cancers, including multiple myeloma (MM), where they drive onco-
genesis, therapy resistance and malignant cell survival largely by up-
regulating genes that suppress cancer-cell apoptosis. As such, the NF-κB
pathway represents an attractive therapeutic target in oncology [1–4].
However, while with an increased understanding of cancer core vul-
nerabilities, there has been a corresponding development of effective
targeted therapeutics, leading to improved clinical outcomes in on-
cology, pharmacologically targeting the NF-κB pathway has proven an
insurmountable challenge. This dismal outcome of the 30-year search
for a clinically useful NF-κB inhibitor is epitomised by the ill-fated
pursuit of agents targeting IKKβ, the molecular gatekeeper of the cel-
lular pathways for NF-κB activation, which, following its discovery in
1997, had re-focused the drug-discovery effort to therapeutically block
NF-κB [2,5,7]. However, this effort came to an abrupt end 10 years
later, when IKKβ-targeting agents were found to cause severe systemic
inflammation and animal lethality in mouse models [7]. Further studies
confirmed this paradoxical pro-inflammatory effect of IKKβ inhibitors
in human trials, while exposing a series of additional on-target dose-
limiting toxicities, including hepatotoxicity and numerous im-
munodeficiencies, resulting from the general suppression of the NF-κB
pathway [2,8,9].
The barrier to effectively targeting NF-κB has been to achieve safe
NF-κB inhibition, which requires preserving the pleiotropic and ubi-
quitous physiological functions of the NF-κB pathway [2,6,10]. Since
constitutive NF-κB activity drives oncogenesis by upregulating anti-
apoptotic genes [2,10], we sought to overcome this barrier by targeting
the non-redundant, cancer-specific downstream effectors of the onco-
genic NF-κB survival function, rather than NF-κB itself [11]. We tested
this principle in MM, an incurable plasma-cell malignancy and the
paradigm for NF-κB-driven cancers [12]. Virtually all MM cases display
constitutive NF-κB signalling, an addiction to NF-κB activity for sur-
vival, and susceptibility to apoptosis upon IKKβ/NF-κB-pathway
inhibition [1]. As such, MM provided an ideal testing ground for our
novel therapeutic approach.
The current treatments for MM include chemotherapy, steroids,
immunomodulatory (IMiD) agents (i.e. thalidomide, lenalidomide and
pomalidomide), and proteasome inhibitors (i.e. bortezomib and carfil-
zomib), with newer agents in development including anti-CD38 anti-
body and CAR-T immunotherapy, and autologous stem-cell transplan-
tation being indicated in selected patients. However, none of these
treatments generally achieves lasting remissions, leading to relapse
and/or refractory disease [12–15]. Moreover, while IMiDs and pro-
teasome inhibitors have been shown to impact NF-κB signalling, these
agents have broad biological activities, lack specificity for the NF-κB
pathway, and, importantly, afford their clinical effects in MM via NF-
κB-independent mechanisms [1,16,17]. Consequently, there is an ur-
gent need for an entirely new approach to safely block aberrant NF-κB
signalling in MM and other NF-κB-driven cancers.
Recently, we identified the complex formed by NF-κB-regulated
antiapoptotic factor, GADD45β, and the c-Jun N-terminal kinase (JNK)-
activating kinase, MKK7, as an essential, cancer-selective survival
module downstream of NF-κB and novel therapeutic target in MM
[11,18–20]. We showed that elevated GADD45B expression in MM cells
correlates with poor clinical outcome and promotes malignant cell
survival by suppressing JNK-driven apoptosis through a mechanism
that depends upon the GADD45β-mediated binding to and inhibition of
MKK7 [11,21]. Crucially, most normal cells do not require GADD45β
for their survival [22], and, unlike mice lacking the NF-κB/RelA subunit
or any core components of the IKK complex, Gadd45b knock-out mice
are viable, fertile and die of old age [2,23,24]. Therefore, to selectively
block oncogenic NF-κB signalling in MM, we therapeutically targeted
the downstream GADD45β/MKK7 survival complex. Accordingly, we
developed a D-tripeptide inhibitor of this complex, DTP3, which spe-
cifically binds to MKK7 via a mechanism that effectively disrupts the
GADD45β/MKK7 interaction [11,21]. As a result of this therapeutic
mode of action, DTP3 specifically kills MM cells exhibiting elevated
GADD454β expression, ex vivo and in vivo, by inducing MKK7/JNK-
Fig. 1. The secondary pharmacology and drug-
drug interaction potential of DTP3. A, The
profile of DTP3 in radio-ligand competition
binding assays against a panel of 80 validated
drug targets (see also Supplementary Fig. 1A).
Values represent the mean percentage of in-
hibition of the binding of target-specific con-
trol ligands in the presence of DTP3 (10 μM)
relative to the binding observed in the absence
of DTP3 (n= 2). Inhibition greater than 50%
was considered to represent a significant effect
for the purpose of conducting further in-
vestigations. 48, μ-opioid peptide (MOP) re-
ceptor; 64, Sigma receptors (non-selective). B,
Time-dependent inhibition assays showing the
DTP3-mediated inhibition of the indicated cy-
tochrome P450 (CYP) isoforms in the absence
(0min) or presence of a 30-minute pre-in-
cubation (30min) of human liver microsomes
with or without NADPH, as shown. IC50 values
denote the concentrations of DTP3 resulting in
a 50% inhibition of the formation of CYP iso-
form-specific metabolites. C, Enzymatic assays
showing the fold induction of the indicated
CYP isoforms following a 72-hour treatment of
human hepatocytes with either DTP3, at the
indicated concentrations, or isoform-specific
control inducers, relative to vehicle control.
Values denote the mean fold inductions± SD
(n= 3) of isoform-specific metabolite levels
following hepatocyte treatment. O, omepra-
zole; P, phenobarbital; R, rifampicin.
L. Tornatore, et al. Toxicology Reports 6 (2019) 369–379
370
driven apoptosis, and, importantly, does not appear to be toxic to
normal tissues. Strikingly, upon systemic administration, DTP3 caused
a complete regression of established subcutaneous MM xenografts in
mice, while extending animal survival in orthotopic MM models, with
good tolerability and no apparent adverse effects. Due to its mode of
action, operating downstream of NF-κB, DTP3 also exhibits the capacity
to synergise with bortezomib and bypass drug resistance to conven-
tional anti-MM therapies, including steroids, IMiDs and proteasome
inhibitors.
Therefore, to translate these advantageous pharmacological prop-
erties into healthcare benefit, we sought to initiate clinical trials of
DTP3 in patients with relapsed or refractory MM. In this study, we
report the results from the preclinical safety pharmacology, toxicology,
PK and PD studies of DTP3, leading to the regulatory approval for
clinical trials of this novel anticancer candidate therapeutic in patients
with relapsed or refractory MM. Our results demonstrate that DTP3
displays on-target-selective pharmacology, no significant adverse ef-
fects against vital organ systems, and favourable PK and absorption,
distribution, metabolism and excretion (ADME) profiles, while re-
taining its therapeutic efficacy following intravenous bolus adminis-
tration. DTP3 was tolerated upon daily administration over a 28-day
period in both rodent and non-rodent species, demonstrating no target-
organs of toxicity, no adverse effect precluding its clinical development
in oncology, and a wide preclinical therapeutic window. As such, DTP3
introduces into oncology a novel therapeutic mode of action selectively
blocking pathogenic NF-κB survival signalling in cancer cells, while
overcoming the dose-limiting toxicities of conventional IKKβ/NF-κB-
targeting drugs. Indeed, due its cancer-selective pharmacology and
capacity to bypass drug resistance and synergise with bortezomib, DTP3
represents a significant clinical opportunity, which could translate into
a safe and effective anticancer therapeutic to treat patients with re-
lapsed/refractory MM and potentially other recalcitrant NF-κB-driven
cancers.
2. Results
2.1. Secondary pharmacology and drug-drug interactions
We previously reported that DTP3 displayed no significant off-target
effects in a panel of 142 human kinases, and that its therapeutic activity
in sensitive MM cell lines was completely abrogated by the RNA in-
terference-mediated inhibition of MKK7, its pharmacological target,
suggesting it exhibits high target specificity [11]. To further evaluate
the potential of DTP3 for mediating secondary pharmacological effects,
ahead of the regulatory submissions, we used a conventional in-vitro
selectivity screen. Except for a weak interaction with Sigma (non-se-
lective) and μ-opioid peptide (MOP) receptors, DTP3 demonstrated no
significant off-target effect when profiled in radioligand competition
binding assays against a panel of 80 validated drug targets, including
enzymes, receptors, and transporters (Fig. 1A, Supplementary Fig. 1A).
On further investigation, DTP3 displayed a low binding affinity for
Sigma receptors, with an IC50 value of 13 μM and inhibition constant
(Ki) of 10 μM (Supplementary Fig. 1B-C). At higher concentrations (i.e.,
100 μM), DTP3 also exhibited a weak antagonist effect on Sigma
(Supplementary Fig. 1D). While these weak in-vitro interactions of DTP3
with Sigma and MOP receptors identify a potential for secondary
pharmacological activities, these effects were observed at relatively
high drug concentrations, significantly higher than the therapeutically
effective in-vivo plasma concentrations [11], and moreover, are not
relevant, at least from a regulatory perspective, for a clinical drug
candidate in oncology.
To further understand the pharmacology of DTP3, we examined the
potential of this agent for mediating drug-drug interactions via drug-
metabolising enzymes of the cytochrome P450 (CYP) family. Upon
evaluation in human liver microsomes, ex vivo, DTP3 demonstrated a
weak time-dependent inhibitory effect on CYP3 A4, but no reversible
inhibition of any other major human CYP isoform, as shown by its re-
latively high IC50 values in the presence or absence of NADPH. (Fig. 1B,
Supplementary Fig. 1E-F). Moreover, DTP3 did not induce any major
human CYP isoform in human hepatocytes, ex vivo (Fig. 1C). Given the
weak NADPH-dependent inhibitory effect of DTP3 on CYP3 A4 and the
high frequency of drug-mediated effects on this CYP isoform by the
medicines in current clinical use, this potential for engaging in drug-
drug interactions via CYP3 A4 poses no problem to the clinical devel-
opment of DTP3 in oncological patients. Collectively, our findings un-
derscore the overall limited potential of DTP3 for mediating preclusive
off-target effects and some potential for mediating weak drug interac-
tions via CYP3 A4.
2.2. Non-specific cytotoxicity and genotoxicity
We investigated the non-specific cytotoxic potential of DTP3 in the
human hepatocellular carcinoma cell line, HepG2, which does not ex-
press GADD45β (Supplementary Fig. 2A), using a multi-parametric
toxicity assay, in vitro. As expected, upon evaluation at concentrations
up to 100 μM, DTP3 induced no change in any of the cytotoxicity
parameters investigated, including cytochrome c release (Fig. 2), thus
excluding any non-specific drug-dependent cytotoxic effect in this ex-
perimental system. To investigate the mutagenic potential of DTP3, we
conducted a Good Laboratory Practice (GLP)-compliant bacterial re-
verse mutation study, using five different histidine-requiring strains of
S. typhimurium, each reporting on distinct classes of genetically active
compounds. As shown in Supplementary Fig. 2B-C, whereas control
agents caused a significant increase in the number of revertant colonies
with each of the tester strains evaluated, the exposure to DTP3 resulted
in no change in colony numbers, compared to vehicle control, irre-
spective of the presence or absence of metabolic activation by Aroclor
1254-induced rat liver post-mitochondrial S9 fraction. Hence, DTP3
exhibited no mutagenic activity in this assay.
2.3. The safety pharmacology of DTP3
We performed a GLP-compliant human ether-à-go-go related gene
(hERG) study, in vitro, to assess the potential of DTP3 for causing QT-
Fig. 2. Absence of off-target hepatocellular cytotoxicity by
DTP3. Table reporting the results of cytotoxicity assays
performed in HepG2 cells following treatment with DTP3
or positive control compounds (i.e., carbonyl cyanide and
chlorpromazine), as indicated, at the concentrations of
0.04, 0.1, 0.4, 1.0, 4.0, 10, 40 and 100 μM. Reported is the
minimum effective concentration (MEC) of each com-
pound resulting in a significant cytotoxic effect relative to
vehicle control. Values denote means. -, not applicable; *,
non-statistically significant fit.
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interval prolongation. As shown in Fig. 3A, DTP3 produced no inhibi-
tion of the potassium ion channel, hERG, when used at the concentra-
tion of 150 μg/mL. By contrast, exposure to the selective rapid delayed
rectifier current (IKr) blocker, E-4031, resulted in a complete suppres-
sion of hERG-mediated tail currents. These results demonstrate the low
potential of DTP3 for causing a long-QT syndrome, a common cause of
life-threatening cardiac arrhythmias.
Next, we conducted a safety risk assessment of DTP3 on vital organ
systems by performing GLP-compliant safety pharmacology studies, in
vivo, following short infusion (over 10min) by the intravenous route of
administration, as the clinical therapeutic route of choice. Consistent
with the results from the hERG study (Fig. 3A), intravenous DTP3 ad-
ministration at doses up to 25mg/kg produced no clinically significant
effect on any of the cardiovascular or haemodynamic parameter
evaluated in the conscious, freely moving dog, including ECG wave-
form, QTC interval, mean arterial pressure (MAP), and heart rate
(Fig. 3B-D). A transient increase in heart rate was noted in some ani-
mals at the first 2 time points, within 10min of dosing, but this increase
was not dose-dependent and therefore considered not to be drug re-
lated. DTP3 was similarly assessed for potential adverse effects on re-
spiratory function in the freely moving conscious rat. As shown in
Fig. 3E–G, upon rapid DTP3 intravenous infusion at the dose levels of
15, 40 or 100mg/kg, drug-treated animals demonstrated no significant
change in any respiratory parameter, including tidal volume, respira-
tion rate and minute volume, as compared to the vehicle-treated group.
The same dose levels and regimen of administration were used in the
rat to also evaluate the effects of DTP3 on the CNS, according to Irwin’s
method. DTP3 induced no change in body temperature, nor general
Fig. 3. The safety pharmacology of DTP3. A,
hERG assays showing the percentage of in-
hibition of hERG-dependent outward tail cur-
rents in HEK-293 cells following treatment
with vehicle (CTR), DTP3 or the selective IKr
blocker, E-4031, at the indicated concentra-
tions. Values represent the mean
percentages± SD (n= 3) of the recorded cur-
rent inhibition relative to pre-treatment vol-
tage-clamp recordings from individual HEK-
293 cells. B-D, Radio-telemetry recordings of
the indicated cardiovascular parameters at the
time shown in conscious, freely moving dogs
following rapid intravenous infusion of vehicle
control or the reported doses of DTP3. B, bpm,
beats per minute. C, QTc interval, corrected QT
interval. D, MAP, mean arterial blood pressure.
E-G, Whole-body plethysmography recordings
of the indicated respiratory parameters at the
time shown in conscious, freely moving rats
following rapid intravenous infusion of vehicle
control or the reported doses of DTP3. B-G,
Values denote means± SD; n=4 (B-D), n=6
(E-G). H, Heat-map showing the number of rats
exhibiting post-dosing abnormalities in auto-
nomic or locomotor activity and/or general
behaviour (n= 6), according to Irwin's
method, at the times shown after treatment
with vehicle control or the indicated doses of
DTP3 as in (E-G). A-H, assays were conducted
in compliance with GLP.
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behaviour, nor autonomic nor motor activity at the dose level of either
15 or 40mg/kg (Fig. 3H). A mild and transient increase in locomotor
activity was observed in a minority of the animals treated at the dose
level of 100mg/kg (Fig. 3H), but this effect was considered not to be
drug-related, as it was not observed in the 28-day repeat-dose toxicity
study, and DTP3 was found not to cross the blood-brain barrier to any
significant extent (discussed below). Furthermore, such potential effect
on CNS function would be of no relevance from a regulatory perspective
for the safety assessment of an oncological drug. No further changes in
body temperature, nor behaviour were observed following DTP3
(caption on next page)
L. Tornatore, et al. Toxicology Reports 6 (2019) 369–379
373
administration at 100mg/kg (Fig. 3H). We concluded from these GLP-
compliant safety pharmacology studies that DTP3 does not significantly
adversely affect the CNS, nor the cardiovascular nor respiratory system,
at any of the dose levels investigated. Collectively, these results un-
derpin the excellent safety pharmacology of DTP3 and support the
progression of this novel candidate therapeutic into clinical evaluation
in oncology.
2.4. The PK profile of DTP3
A series of PK and toxicokinetic (TK) studies were conducted in
mouse, rat and dog. The dose-related PK values derived from these
studies demonstrated that, following intravenous administration of
DTP3, maximum plasma concentrations (Cmax) and systemic exposures
(AUC0-t) increased in a linear manner with dose level in each species,
indicating that there was no saturation of clearance at the higher dose
levels (Supplementary Fig. 3A-C). There were no gender differences in
PK parameters (Supplementary Fig. 3A–B). As expected, the mean Cmax
values of DTP3 coincided with the end of the injection or infusion.
Thereafter, the plasma concentrations of DTP3 declined in a biphasic
manner in both rodent and non-rodent species, demonstrating a marked
distribution phase followed by a longer terminal elimination phase.
Based on these data, the overall mean volume of distribution (Va)
values were approximately 2 L/kg in mouse, 17 L/kg in rat, and 9 L/kg
in dog, indicating that DTP3 largely distributed into tissues across
species (Fig. 4A). The mean plasma clearance (CL) of DTP3 was
moderate in all species, exhibiting values of approximately 27mL/min/
kg, 18mL/min/kg and 11mL/min/kg in mouse, rat and dog, respec-
tively, corresponding in each case to approximately 30% of liver blood
flow (Fig. 4A). These values are in keeping with a slow rate of elim-
ination of DTP3, resulting in the relatively long overall mean terminal
half-lives (t½) of 19 and 11 h in rat and dog, respectively (Fig. 4A). T½
values appeared to be instead considerably shorter in mouse, ranging
between 1 and 1.5 h. Upon repeated rapid daily infusion, the corre-
sponding mean Cmax and AUC0-t values were slightly higher on day 28
than day 1 in both rat and dog, reflecting the long terminal plasma half-
lives of DTP3 in these species and, again, were essentially proportional
with respect to dose level, indicating that there was no marked accu-
mulation of DTP3, nor any alteration in systemic clearance, with in-
creased dose or repeated administration (Supplementary Fig. 3A–B).
From these preclinical data, we sought to project a human plasma
half-life, using a conventional scaling methodology based on inter-
species differences in liver blood flow, while assuming that systemic
clearance would be the same proportion of liver blood flow in all spe-
cies, and that volume of distribution would also be the same [25,26].
The resulting projections for human plasma half-life were 33 and 18 h
on the basis of the PK profiles observed in rat and dog, respectively,
suggesting the suitability of DTP3 for a clinically advantageous, long-
term intravenous dosing regimen. Interestingly, at least in the mouse,
the mean systemic exposures and elimination half-lives of DTP3 were
broadly equivalent within a wide dosing range, following either sub-
cutaneous or intravenous injection (Supplementary Fig. 3C-D),
Fig. 4. The PK and ADME profiles of DTP3. A, Table reporting the mean values of the main PK parameters of DTP3 in mouse, rat and dog following intravenous
administration by rapid infusion (rat and dog) or injection (mouse). t½, terminal half-life; CL, clearance; Va, volume of distribution area. B, In-vitro plasma protein
binding (PPB) values of DTP3 in mouse, rat, dog and man, as shown. Values denote the percentages of bound drug fraction. C, Representative quantitative whole-
body autoradiographs (QWBA) showing the tissue distribution of DTP3-related radioactivity in rat at the times indicated, following rapid intravenous infusion of
15mg/kg of [14C]-labelled DTP3. D, Liquid scintillation counting (LSC) showing the relative excretion of DTP3-related radioactivity in urine, faeces and cage washes
in rats (columns) at the times indicated following administration of [14C]-labelled DTP3 as in (C). Also shown are the mean cumulative excretion values of DTP3-
related radioactivity (line). Values denote the mean percentages of total administrated radioactivity (n=3). E, High-resolution LC–MS/MS analysis showing the
mean percentages of the indicated radioactive metabolites in chromatographic profiles from plasma, urine and faeces at the times shown following administration of
[14C]-labelled DTP3 as in (C). Compounds are identified by the following matrix codes: P, plasma (n=6); U, urine (n=3); F, faeces, (n=3). Metabolites assigned
by LC–MS/MS are as follows: P9, U3 and F4, product of the oxidative deamination of DTP3; P7 and F3, methoxy-DTP3.
Fig. 5. The therapeutic efficacy of DTP3 in a
mouse MM xenograft model upon intravenous
bolus injection by a clinically suitable dosing
schedule. A, Volumes of subcutaneous U266
MM xenografts in mice at the time shown fol-
lowing treatment with vehicle control (CTR) or
10mg/kg of DTP3, according to the indicated
intravenous dosing schedule. Statistical com-
parisons are shown between the vehicle-
treated group and the group treated with DTP3
once every day. B, Images of representative
tumours from the indicated treatment groups
in (A) at day 14. C, Trypan blue exclusion as-
says showing the number of live MM
(CD138+) cells in tumours from the groups in
(A) at the experimental endpoint on day 14. A
and C, Values denote means± SEM (vehicle-
treated group, n=6; DTP3-treated groups,
n= 3). **, p< 0.01; ***, p< 0.001.
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suggesting a good relative systemic bioavailability of DTP3 by the
subcutaneous administration route, which could provide a valuable
adjunct to the clinical use of this novel agent.
2.5. The ADME profile of DTP3
The in vitro plasma protein binding (PPB) of DTP3 was consistently
low across species, with percentage values of bound drug fraction of
around 20–40% in mouse, dog and man, and somewhat higher values
(caption on next page)
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and a degree of variability between studies in rat (Fig. 4B). The tissue
distribution of DTP3 was investigated upon intravenous administration
of [14C]-labelled drug material to the rat. As shown in Fig. 4C, DTP3
rapidly and extensively distributed to most tissues. The highest levels of
radioactivity were recorded in urine, liver, kidney cortex, bile ducts and
urinary bladder wall (Supplementary Fig. 3E), denoting the main routes
of elimination (discussed below). Notably, no DTP3-related radio-
activity was detected in brain, nor spinal cord, indicating that DTP3 did
not cross the blood-brain barrier to a significant extent (Fig. 4C, Sup-
plementary Fig. 3E).
Approximately 90% of the total administered radioactivity was ex-
creted in urine and faeces within 48 h of dosing (Fig. 4D). Renal
elimination was relatively low, comprising approximately 30% of the
total administered dose. Faecal elimination represented the pre-
dominant route of excretion, with approximately 60% of radioactivity
being eliminated by this route (Fig. 4D), suggesting some biliary in-
volvement. The remaining radioactivity was largely recovered in cage
washings, and no more than 0.5% of the total administered drug ma-
terial was detected in carcasses at the end of the sampling period, in-
dicating that DTP3 had not accumulated in tissues.
Upon evaluation of its stability in hepatocytes from rat, dog,
monkey and man, ex vivo, DTP3 displayed no significant metabolism in
any of these species (Supplementary Fig. 3F), suggesting that it is a low-
clearance compound, an advantageous drug-like characteristic. In
keeping with these ex-vivo results, no major drug metabolites were
detected in either plasma, urine or faeces, following intravenous ad-
ministration of DTP3 to the rat (Fig. 4E). In plasma, DTP3 was by far the
most abundant radiolabelled chemical species (Fig. 4E; see also Sup-
plementary Fig. 3G). The LC–MS/MS analysis of plasma demonstrated
the presence of up to eight DTP3 metabolites, but collectively these
amounted to no more than 15% of the total radioactivity (Fig. 4E,
Supplementary Fig. 3G). Similarly, DTP3 accounted for 89% and 74%
of the total radioactivity detected in urine and faeces, respectively
(Fig. 4E). We concluded that DTP3 is not significantly metabolically
cleared, in vivo. Collectively, our findings demonstrate the favourable
PK and ADME profiles of DTP3 and reinforce the clinical potential of
this novel candidate anticancer therapeutic.
2.6. The therapeutic efficacy of DTP3 upon intravenous bolus injection
We previously showed that DTP3 was effective in eliminating MM
xenografts in both subcutaneous and orthotopic mouse models, upon
administration by continual infusion [11]. However, since this admin-
istration regimen is impractical for clinical use and development, we
sought to determine whether DTP3 retained its therapeutic efficacy
following administration by intravenous bolus injection, using a pre-
viously characterised subcutaneous MM xenograft model and different
potential clinical dosing schedules. As shown in Fig. 5A–B, at the ex-
perimental end-point, all mice in the vehicle-treated group had devel-
oped large tumours, whereas mice treated with 10mg/kg of DTP3 once
every day, once every other day, or once every 3 days demonstrated a
dramatic tumour shrinkage. By contrast, DTP3 administration once a
week produced no significant effect on tumour volume (Fig. 5A). In-
terestingly, an analysis of residual MM cells in mice established that
DTP3 achieved a virtually complete elimination of any viable CD138+
cells when administered once every day or once every other day,
whereas DTP3 administration once every 3 days was significantly less
effective in killing MM cells (Fig. 5C). These data demonstrate the po-
tent therapeutic efficacy of DTP3 upon administration by a clinically
advantageous intravenous bolus injection schedule and establish the
optimal clinical dosing frequency of approximately once every other
day for the first-in-human trial of DTP3 in MM patients.
To verify the therapeutic mode of action of DTP3, following ad-
ministration by the proposed clinical intravenous dosing schedule, we
evaluated the induction of JNK signalling and apoptosis in tumour cells
from subcutaneous MM xenografts. As shown in Supplementary
Fig. 4A–B, DTP3 administration by this dosing schedule induced a
strong pharmacodynamic response, denoting therapeutic target en-
gagement, in virtually all CD138+ cells within tumours, as shown by
the near-complete shift in the signals reporting JNK phosphorylation
and caspase-3 cleavage, and the marked increase in the percentage of
MM cells exhibiting a sub-G1 DNA content, a hallmark of apoptosis. By
contrast, DTP3 administration had no effect on ERK phosphorylation in
MM cells, confirming the specificity of its therapeutic mode of action, in
vivo (Supplementary Fig. 4A). These results confirm the DTP3 mode of
action, in vivo, and demonstrate the suitability of the FACS-based
methodology for detecting a cancer-selective pharmacodynamic re-
sponse in MM patients from the first-in-human study of DTP3.
2.7. The toxicological profile of DTP3
Dose-ranging studies were conducted in rodent and non-rodent
species to determine the maximum tolerated dose (MTD) of DTP3 in
these species. In the rat, DTP3 administration resulted in the death of
both animals treated at the dose level of 150mg/kg. Two out of four
animals treated with 125mg/kg of DTP3, as well as two controls, also
died (data not shown). All deaths occurred during or immediately after
dosing, and there were no drug-related clinical or pathological findings
in any of the decedents. Conversely, DTP3 was tolerated at dose levels
up to 100mg/kg, causing only mild and transient clinical signs and no
clinically significant pathological changes, nor any changes in body
weight, haematology or clinical chemistry parameters. Accordingly, the
dose level of 100mg/kg was declared the MTD in the rat.
The GLP-compliant 28-day repeat-dose toxicity study was therefore
conducted upon daily rapid intravenous infusion of DTP3 in the rat at
the dose levels of 15, 40 and 100mg/kg/day (Supplementary Fig. 5A).
Delayed-onset toxicity and reversibility of toxicity were assessed fol-
lowing an additional 28-day treatment-free period (Supplementary
Fig. 5A). The vast majority of the over one hundred animals given DTP3
completed the 28-day treatment period with no or only few minor
adverse effects. Post-dosing observations were limited to minor and
transient clinical signs, such as swollen face, head and/or muzzle and
semi-closed eyes, only noted in the animals receiving 100mg/kg/day of
DTP3 (Fig. 6A). Clinical signs were invariably observed immediately
after dosing and generally resolved within 1 h and in all cases had
disappeared by the end of the day. There were no ophthalmic findings,
nor any treatment-related changes on body weight nor food consump-
tion, nor were there any effects on haematology, clinical chemistry or
Fig. 6. The toxicological profile of DTP3. A, Heat-map showing the number of rats manifesting the indicated post-dosing observations at the times shown following
daily rapid intravenous infusion of vehicle control or the specified doses of DTP3 during the 28-day repeat-dose toxicity study (please refer to Supplementary Fig. 5B
for the list of in-life procedures undertaken). B, Table reporting the number of rats exhibiting kidney tubular basophilia at microscopic observation at the terminal or
recovery kill, as shown, following treatment with vehicle control or DTP3 as in (A). Also reported is the severity of the microscopic renal findings (please refer to
Supplementary Fig. 5D-E for the list of post-mortem procedures undertaken). C, Table reporting the maximum tolerated dose (MTD) and no observed adverse effect
level (NOAEL) of DTP3 in the rat. D, Heat-map showing the number of dogs manifesting the indicated post-dosing observations at the times shown following daily
rapid intravenous infusion of vehicle control or the specified doses of DTP3 during the 28-day repeat-dose toxicity study (please refer to Supplementary Fig. 5B for the
list of the in-life procedures undertaken). E, Table reporting the number of dogs exhibiting fasciitis/fibrosis at the indicated injection sites at microscopic observation
at the terminal or recovery kill, as shown, following treatment with vehicle control or DTP3 as in (D). Also reported is the severity of the microscopic finding (please
refer to Supplementary Fig. 5G for the list of post-mortem procedures undertaken). F, Table reporting the MTD and NOAEL of DTP3 in the dog. A–B and D-E, M, male;
F, female. B and E, Grade 1, minimal; grade 2, slight; grade 3, moderate; grade 4, severe.
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urinalysis parameters which were considered to be drug-related or
toxicologically significant (Supplementary Fig. 5B-C; see list of in-life
procedures).
At the terminal and recovery kills, there were no treatment-related
changes in organ weights, nor any macroscopic findings suggestive of
either a local or systemic effect of DTP3 (Supplementary Fig. 5D).
Microscopic findings were confined to a minor increase in the incidence
and severity of kidney tubular basophilia, noted in a few rats treated at
the dose level of 100mg/kg/day (Fig. 6B; see also Supplementary
Fig. 5D-E). In the absence of any other findings or any urinalysis or
clinical pathology correlates (Supplementary Fig. 5C), this minor his-
tological change was considered not to be adverse nor, consequently,
dose limiting. At the recovery kill, there was a complete reversal of the
microscopic renal findings observed at the terminal kill (Fig. 6B, Sup-
plementary Fig. 5E). We concluded that, following daily infusion over a
28-day period in the rat, DTP3 was tolerated at dose levels up to
100mg/kg/day. Accordingly, the No Observed Adverse Effect Level
(NOAEL) in this species was considered to be the maximum adminis-
tered dose of 100mg/kg/day (Fig. 6C).
During the dose-ranging study in the dog, there were no decedents.
In the only animal treated at the dose level of 75mg/kg, DTP3 ad-
ministration produced vomiting, which was considered to be dose
limiting (data not shown). Conversely, DTP3 was tolerated at dose le-
vels up to 50mg/kg/day, causing only mild and transient clinical signs,
and no drug-related changes in bodyweight, nor any clinical pathology,
nor macroscopic nor microscopic parameters. Based on these results,
the dose level of 50mg/kg was declared the MTD in the dog.
Accordingly, the GLP-compliant 28-day repeat-dose toxicity study
in this species was conducted upon daily rapid intravenous infusion of
DTP3 at the dose levels of 10, 22 or 50mg/kg/day, and delayed-onset
toxicity and reversibility of toxicity were subsequently assessed, as in
the rat, following an additional 28-day treatment-free period
(Supplementary Fig. 5F). There were no decedents during this study,
and all animals appeared to be healthy at the end of the treatment
period. Transient clinical signs were observed during or immediately
after dosing, intermittently throughout the study, with increased fre-
quency and broader range with the higher dose (Fig. 6D). At the lower
dose levels, there were only a few minor post-dosing observations. At
50mg/kg/day, the most common clinical signs consisted of red body
and/or ears, swollen ears, eyes and/or eyelids, mild body tremors, semi-
closed eyes, and visible nictitating membrane (Fig. 6D). As in the rat, all
clinical signs were rapidly reversible, generally resolving within 1 h of
dosing and in all cases by the end of the day. In one animal investigated
during the dose-ranging study, clinical signs were only marginally at-
tenuated by prophylactic anti-histamine treatment with Phenergan,
suggesting that they were not of an allergic nature (data not shown) ref
[27]. Therefore, since all post-dosing observations were both rapidly
and spontaneously reversible, and immunotoxicity evaluation is not
required for the preclinical safety assessment of an oncological drug
candidate, these effects were considered not to be dose limiting.
Apart from a transient and isolated increase in heart rate, which was
within the normal range for the dog, at 50mg/kg, there were no drug-
related changes in electrocardiography (ECG) parameters, nor wave-
form morphology (data not shown). As in the rat, there were no
treatment-related effects on body weight, food consumption, nor any
haematology, clinical chemistry or urinalysis parameters at any dose
level investigated, nor was there any drug-related ophthalmic change
(Supplementary Fig. 5B; see list of in-life procedures). At the terminal
kill, there were no treatment-related changes in organ weight, nor any
macroscopic changes, except for a slightly increased incidence of red
appearance at some injection sites (Supplementary Fig. 5G).
Microscopically, this minor finding correlated with a mild drug-related
increase in the incidence of fasciitis/fibrosis at two of the injection sites
(Fig. 6E). There were no other microscopic findings which were sug-
gestive of either a local or systemic effect of DTP3. Indeed, all other
tissues were either histo-pathologically unremarkable or the findings
were minor, infrequent and/or consistent with the typical pattern ob-
served in animals of the same strain and age (Supplementary Fig. 5G).
Following the recovery period, there was a complete reversal of the
local findings at injection sites at the terminal kill (Fig. 6E). We con-
cluded that, following repeated rapid daily infusion, DTP3 was toler-
ated in the dog at dose levels up to 50mg/kg/day. Accordingly, the
NOAEL of DTP3 in this species was considered to be the maximum
administered dose of 50mg/kg/day (Fig. 6F). Collectively, the metho-
dical and extensive investigations conducted in the 28-day repeat-dose
toxicity studies underscore the tolerability of DTP3 in both rodent and
non-rodent species, with no target organs of toxicity, no preclusive
adverse effect and no specific risk identified for the progression of this
novel therapeutic into clinical evaluation in oncology.
2.8. Safety margins of exposure and starting clinical dose level
Based on the preclinical pharmacology and toxicology data and
cancer-selective therapeutic mode of action of DTP3, we sought to in-
itiate a phase I trial of this novel anticancer agent in patients with re-
lapsed or refractory MM. To derive the clinical starting dose level and
safety margin of exposure for this first-in-human study of DTP3, the rat
was considered to be the most sensitive toxicological species, as based
on the lowest values for unbound DTP3 fraction (Fig. 4B), the systemic
exposure at the NOAEL in this species generated the most conservative
clinical projections (Supplementary Fig. 3A–B). Upon allometric scaling
by a conventional factor of six, the NOAEL in the rat corresponded to a
human dose equivalent of 16.7mg/kg, which was then reduced by a
further factor of 4.2 to correct for differences in PPB between rat and
man, using the most conservative values for each species (i.e., 80% for
rat and 19% for man; Fig. 4B), yielding a human dose equivalent for
unbound drug fraction of approximately 4.0 mg/kg. An additional
safety margin of eight folds was subsequently applied to obtain the
clinical starting dose level of 0.5mg/kg/day.
To estimate the safety margins of exposure relative to unbound
DTP3, the mean area under the curve (AUC) values in rat and dog at the
NOAEL were compared to the mean AUC derived in mouse at the
therapeutically effective dose level of 10mg/kg (Supplementary
Fig. 3A-C; see also Fig. 5A-C). After correcting for inter-species differ-
ences in PPB, using either the most or least conservative values
(Fig. 4B), the estimated safety margins of exposure relative to unbound
drug ranged from approximately 5 to 15 folds in rat and 15 to 20 folds
in dog, thus underscoring the wide preclinical therapeutic window of
DTP3. Accordingly, the clinical protocol stipulates a potential dose es-
calation up to a maximal clinical dose of 20mg/kg, corresponding to a
40-fold increment over the starting dose level. Indeed, as in the first-in-
human phase I study, DTP3 is administered three times per week by a 1-
hour infusion, rather than once every day by a 10-minute infusion, the
risk to patients is likely to be significantly lower than in preclinical
species, owing to the reduced dosing frequency and projected relative
Cmax values.
3. Discussion
Here, we report the safe and target-selective pharmacology of the
first-in-class GADD45β/MKK7 inhibitor, DTP3. We show that DTP3
exhibits good tolerability, no target organs of toxicity and no preclusive
adverse effects upon daily repeat-dose administration in either rodent
or non-rodent species, resulting in a wide safety margin of exposure.
DTP3 also displayed good drug-like properties and favourable PK and
ADME profiles, suitable for administration by a clinically advantageous
intravenous bolus schedule. Together with our previously published
results [11], the current data demonstrate that the GADD45β/MKK7-
targeting strategy to pharmacologically inhibit oncogenic NF-κB sig-
nalling succeeds in coupling safety with therapeutic anticancer efficacy,
resulting in ablation of MM xenografts in mouse models and selective
killing of primary human MM cells through a mechanism involving
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JNK-driven apoptosis, whilst producing no significant adverse effect
and none of the dose-limiting toxicities of conventional IKKβ/NF-κB-
targeting drugs [2–6,10]. Collectively, these results underscore the
cancer-selective pharmacology and clinical potential of DTP3 as a safe
and effective anticancer therapeutic in patients with MM and poten-
tially other NF-κB-driven cancers.
Interestingly, the initial results from the first-in-human phase I
study of DTP3 in patients with relapsed/refractory MM confirmed the
clinical capacity of this novel anticancer therapeutic to induce a cancer-
selective pharmacodynamic response, triggering JNK signalling and
apoptosis in MM, but not normal cells of patients, whilst producing no
signs of toxicity and no adverse effects [28], thus providing clinical
proof-of-concept for the novel approach to therapeutically block on-
cogenic NF-κB survival signalling.
Notably, while DTP3 combines favourable drug-like properties, in-
cluding on-target specificity, long plasma half-life and good bioavail-
ability, the safety and cancer-selective pharmacology of the therapeutic
approach largely stem from the choice of the drug target and its bio-
logical properties. Crucially, in this respect, GADD45β displays tissue-
restricted function and is dispensable for the survival of most normal
cells [22,23]. Beyond these GADD45β-dependent properties, the ther-
apeutic target is a protein-protein interaction, rather than a lone mo-
lecule, and both GADD45β and MKK7 play biological roles outside their
involvement in the GADD45β/MKK7 complex and, significantly, retain
these roles, including MKK7 enzymatic function, upon complex dis-
ruption by DTP3 [11]. This therapeutic mechanism enhances the se-
lectivity of the approach, as well as its safety.
The positioning of the GADD45β/MKK7 survival module down-
stream in the NF-κB pathway further confers additional clinical ad-
vantages on DTP3, including its capacity to bypass MM-cell resistance
to conventional anti-MM therapies, including proteasome inhibitors,
IMiDs and steroids [11,13–15]. Indeed, due to this therapeutic efficacy
in refractory cancer cells and its capacity to synergise with bortezomib,
DTP3 represents a significant clinical opportunity for treating patients
with relapsed or refractory MM.
Yet, while DTP3 produced no significant adverse effects in any of
the animal species investigated, even when administered at elevated
dose levels, there remain some unknowns relating its successful clinical
translation into an effective GADD45β/MKK7-targeting therapeutic in
oncology. Beyond the generic uncertainties associated with any novel
drug candidate, an on-target-specific unknown in the clinical develop-
ment of DTP3 relates to its potential pro-inflammatory adverse effects
in patients. While producing no obvious phenotypes in unchallenged
animals, genetic Gadd45b disruption was shown to enhance local in-
flammation and immune responses in experimental mouse models of
arthritis, multiple sclerosis and oncogenesis [29–31]. Although in some
cases, these effects appeared to be unrelated to the JNK pathway, in
other cases, as in the context of arthritis, they were shown to depend on
MKK7-driven JNK activation [29]. Therefore, DTP3 administration has
the potential to exacerbate pro-inflammatory JNK signalling in patients
with inflammatory or autoimmune comorbidities in which GADD45β/
MKK7 is pathogenically involved. Even so, on the basis of all available
data on DTP3 and results from the abovementioned genetic models,
including the recent observation that myeloid-specific Gadd45b loss
potentiates tumour-associated inflammation via a JNK-unrelated me-
chanism, any potential pro-inflammatory effects of DTP3 are expected
to be both mild and localised, rather than systemic and dose-limiting, as
in the case of IKKβ inhibitors [7,32–35], and therefore most likely
manageable with anti-inflammatory treatment. Similarly, the increased
susceptibility of Gadd45b−/− mice to bacterial infections has been
shown to involve a deregulation of the mitogen-activated protein kinase
kinase kinase (MAPKKK), MAP/ERK kinase kinase 4 (MEKK4)/MAP
three kinase 1 (MTK1) [36], rather than MKK7, and consequently
would be unaffected by DTP3. Moreover, these potential risks asso-
ciated with DTP3 administration represent a major step forward over
the systemic dose-limiting toxicities of global IKKβ/NF-κB inhibition,
and unlike these toxicities, would be acceptable for the development of
a clinical drug candidate in oncology.
Future studies will determine the clinical safety and therapeutic
efficacy of DTP3 in patients with MM and potentially other cancers in
which NF-κB drives oncogenesis via GADD45β [31]. Notwithstanding,
the preclinical safety and on-target-specific pharmacology of DTP3 we
report here, together with the potent and cancer-selective therapeutic
efficacy previously demonstrated in MM cells from patients and mouse
MM xenograft models, and the recently published encouraging clinical
results in MM patients [28], demonstrate that the safe inhibition of the
NF-κB survival pathway is clinically achievable and capable of produ-
cing the desired therapeutic effects, with profound implications in on-
cology, beyond MM. Indeed, the basic principle of targeting a patho-
genically critical axis of the NF-κB pathway, rather than NF-κB globally,
and underpinning the development of DTP3, could be applied to safely
target pathogenic NF-κB signalling also in GADD45β-independent ma-
lignancies and, perhaps, even non-malignant NF-κB-driven diseases.
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